A finding worth understanding

A small study of 24 people with social anxiety disorder found less anxiety during a simulated public-speaking task after CBD than after placebo. NCCIH includes this study in its discussion of the limited human evidence on anxiety. [1] The original paper was published in 2011. [2]

That finding asks an interesting question about a specific situation. It does not answer every question about ongoing symptoms, long-term treatment, other anxiety disorders, or products with different ingredients.

A newer trial shows why the primary outcome matters

A 2024 randomized trial studied a single 400-mg dose of prescription CBD in 50 women with advanced breast cancer and scan-related anxiety. The main comparison—the change in the anxiety score—did not differ significantly from placebo. An exploratory comparison found lower anxiety levels after CBD. [3]

These results justify further study, not a broad treatment promise. A single dose in a specific clinical setting does not establish the benefits of a retail product or ongoing use. The research dose is not a recommendation for self-treatment.

Notice the jump from study to claim

Try writing the research claim in one sentence: “In this group, under these conditions, researchers measured this outcome.” Then compare that sentence with the claim on a product page.

If the product page removes the group, the setting, or the limits, it may sound more certain than the research allows. This is especially important when a brief experiment is used to support a promise about daily life.

Our “early evidence” label is editorial shorthand for the selected sources discussed here. It is not a clinical recommendation or a formal evidence grade.

Take useful questions to your appointment

Describe when anxiety occurs, what it keeps you from doing, and what support you have already tried. Ask what the available evidence means for your particular symptoms and which established treatments should be considered.

If you are considering CBD, show the actual product label and your full medication list to the clinician or pharmacist. Do not infer that a reassuring word such as “calm” on a package answers questions about interactions, effectiveness, or long-term use.

Our reading: curiosity is reasonable. Certainty would require more than a small, situation-specific finding.

Update note

September 28, 2026: added the 2024 scan-related anxiety trial, including its nonsignificant primary outcome and the limits of its exploratory finding.

Sources & scope

  1. NCCIH — Cannabis and cannabinoids: anxiety evidence
  2. Bergamaschi et al. (2011) — CBD and simulated public speaking in social anxiety
  3. Nayak et al. (2024) — Cannabidiol for scan-related anxiety: randomized clinical trial

Sources consulted September 12, 2026; additional trial consulted September 28, 2026. This article explains selected evidence; it is not an exhaustive literature review. Practical reading questions and interpretations are our editorial guidance.

Educational information, not diagnosis or personal treatment advice. No clinician review is claimed. Read our editorial standards or request a correction.